CELZ Creative Medical Technology Holdings, Inc. Stock Quote

CELZ [NASD]

Creative Medical Technology Holdings, Inc.

Index	-	P/E	-	EPS (ttm)	-3.30	Insider Own	0.40%	Shs Outstand	6.45M	Perf Week	13.44%
Market Cap	7.10M	Forward P/E	-	EPS next Y	-0.63	Insider Trans	108.19%	Shs Float	5.77M	Perf Month	-22.11%
Income	-9.80M	PEG	-	EPS next Q	-0.16	Inst Own	9.40%	Short Float	3.39%	Perf Quarter	-81.03%
Sales	0.10M	P/S	70.97	EPS this Y	109.40%	Inst Trans	-6.82%	Short Ratio	0.23	Perf Half Y	-63.90%
Book/sh	1.45	P/B	0.51	EPS next Y	4.80%	ROA	-157.30%	Target Price	10.00	Perf Year	-95.65%
Cash/sh	0.95	P/C	0.78	EPS next 5Y	-	ROE	-217.00%	52W Range	0.59 - 20.00	Perf YTD	-66.52%
Dividend	-	P/FCF	-	EPS past 5Y	15.00%	ROI	-	52W High	-96.30%	Beta	5.05
Dividend %	-	Quick Ratio	24.30	Sales past 5Y	-	Gross Margin	46.70%	52W Low	25.21%	ATR	0.10
Employees	4	Current Ratio	24.30	Sales Q/Q	287.20%	Oper. Margin	-	RSI (14)	36.14	Volatility	14.96% 14.23%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-101.60%	Profit Margin	-	Rel Volume	2.49	Prev Close	0.75
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	839.18K	Price	0.74
Recom	2.00	SMA20	-2.00%	SMA50	-40.61%	SMA200	-77.36%	Volume	2,830,651	Change	-1.33%

Jun-15-22 08:30AM	Creative Medical Technology Holdings Announces Agreement with Greenstone Biosciences, Inc. for Development of a Next Generation iPSC Pipeline for its ImmCelz® Immunotherapy Platform PR Newswire
Apr-29-22 08:40AM	Creative Medical Technology Announces $17 Million Private Placement Priced At-The-Market Under Nasdaq Rules PR Newswire -6.00%
Apr-20-22 08:30AM	Creative Medical Technology Announces Progress in Developing a Reproducible Clinical Grade of the Company's ImmCelz® Product PR Newswire +9.38%
Apr-12-22 08:30AM	Creative Medical Technology to Showcase CaverStem® at American Urological Association Annual Meeting - Largest and Most Prominent Gathering of Urologists in the World PR Newswire -7.08%
Mar-31-22 08:30AM	Creative Medical Technology Signs Master Collaboration Agreement with the University of Miami to Accelerate Development of ImmCelz® Supercharged Autologous Immunotherapy Platform PR Newswire +15.04%
Mar-23-22 08:30AM	Creative Medical Technology Announces Positive Top-Line Results for StemSpine® Pilot Study PR Newswire +82.35%
Mar-10-22 08:30AM	Creative Medical Technology Secures Exclusive Distribution Rights for Cervos Medical's Marrow Cellution Devices for Use in Urology, Gynecology, and Male and Female Sexual Dysfunction PR Newswire
Mar-08-22 08:30AM	Creative Medical Technology to Participate in the 34th Annual Roth Conference PR Newswire -10.74%
Mar-02-22 08:30AM	Creative Medical Technology Appoints Sahil Nock as Chief Commercial Officer PR Newswire
Jan-20-22 07:15AM	Phoenix's Creative Medical Technology uplists to Nasdaq in hopes of making more stem cell treatments American City Business Journals
Nov-09-21 04:45PM	Creative Medical Technology Holdings Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to The Nasdaq Capital Market PR Newswire -7.08%
Oct-12-21 08:15AM	Creative Medical Technology Holdings Reports Positive Data on ImmCelz Immunotherapy Product PR Newswire
Oct-01-21 08:15AM	Creative Medical Technology Holdings Files Provisional Patent on Novel Type 1 Diabetes Immunotherapy Using Exosomes from MyeloCelz Platform PR Newswire +14.00%
Sep-16-21 07:45AM	Creative Medical Technology Holdings, Inc. Engages Established Contact Management Organization to Accelerate Adoption of CaverStem® PR Newswire +5.06%
Aug-09-21 04:43PM	Creative Medical Technology Holdings Announces $3.8 Million Private Placement with Institutional Investors PR Newswire
Jul-20-21 07:45AM	Creative Medical Technology Holdings Announces MyeloCelz The Company's Second Regenerative Immunotherapy Product PR Newswire
Jun-22-21 07:45AM	Creative Medical Technology Holdings Recruits Renowned Stem Cell Clinical Trials Expert to Hyper-Accelerate FDA Clearance PR Newswire
Jun-17-21 07:00AM	Creative Medical Technology Holdings To Present ImmCelz® Subsidiary At World Stem Cell Conference PR Newswire +6.67%
Jun-09-21 08:18AM	Creative Medical Technology Holdings Identifies Synergy Between ImmCelz® Regenerative Immunotherapy and Myeloid Suppressor Cells in Treatment of Type 1 Diabetes PR Newswire +17.12%
May-24-21 07:45AM	Creative Medical Technology Holdings Expands Neurological Application of ImmCelz® into Parkinson's Disease PR Newswire +10.94%
May-20-21 08:45AM	Internationally Renowned Clinician Scientist Camillo Ricordi Head of Diabetes Research Institute Joins Creative Medical Technology Holdings PR Newswire +17.88%

Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Finger Michael H.	Director	Jun 14	Buy	0.70	10,000	7,000	16,502	Jun 14 06:17 PM
Warbington Timothy	President & CEO	Jun 06	Buy	0.92	25,000	22,884	25,087	Jun 07 04:02 PM
Finger Michael H.	Director	May 20	Buy	1.50	6,500	9,750	6,502	May 20 11:09 AM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience